Compare COLM & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COLM | VRDN |
|---|---|---|
| Founded | 1938 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.2B |
| IPO Year | 1998 | N/A |
| Metric | COLM | VRDN |
|---|---|---|
| Price | $54.02 | $33.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | ★ $58.00 | $41.17 |
| AVG Volume (30 Days) | 534.5K | ★ 1.4M |
| Earning Date | 02-03-2026 | 02-26-2026 |
| Dividend Yield | ★ 2.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.37 | N/A |
| Revenue | ★ $3,423,711,000.00 | $70,789,000.00 |
| Revenue This Year | $1.70 | $26,257.62 |
| Revenue Next Year | $1.78 | $4.54 |
| P/E Ratio | $16.00 | ★ N/A |
| Revenue Growth | 2.75 | ★ 23340.07 |
| 52 Week Low | $47.47 | $9.90 |
| 52 Week High | $92.88 | $34.29 |
| Indicator | COLM | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 48.33 | 61.19 |
| Support Level | $52.07 | $31.26 |
| Resistance Level | $55.15 | $34.29 |
| Average True Range (ATR) | 1.58 | 1.30 |
| MACD | -0.09 | 0.09 |
| Stochastic Oscillator | 34.52 | 84.28 |
Columbia Sportswear Co makes outdoor and active-lifestyle apparel, footwear, equipment, and accessories that it sells under four primary brands: Columbia, Sorel, Mountain Hardwear, and prAna. The majority of sales are in the United States, but the company also has remarkable sales in its three other geographic segments: Latin American and Asia-Pacific; Europe, Middle East, and Africa; and Canada. The majority of sales are through wholesale channels, including sporting goods and department stores, but the company also operates its own branded stores in each of its geographic segments. Columbia sources products from around the world and uses contract manufacturers outside the United States, predominantly in Asia to manufacture its various products.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).